Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)

Dalbavancin appears to be a viable candidate for treating BJI/osteomyelitis caused by Gram-positive cocci.